People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness (PALACE)
This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35222
- Alabama (Site ID: 31788)
-
Kontakt:
- Heather Logan
- Telefonnummer: 205-934-6774
- E-mail: heatherlogan@uabmc.edu
-
-
California
-
Los Angeles, California, Forenede Stater, 90035
- University of California, Los Angeles CARE Center (Site ID: 601)
-
Kontakt:
- Aleen Khodabakhshian
- Telefonnummer: 310-557-3798
- E-mail: akhodabakhshian@mednet.ucla.edu
-
San Diego, California, Forenede Stater, 92103
- UCSD Antiviral Research Center (Site ID: 701)
-
Kontakt:
- Dawn Rosenblum
- Telefonnummer: 619-543-8080
- E-mail: drosenblum@health.ucsd.edu
-
San Francisco, California, Forenede Stater, 94110
- University of California, San Francisco (Site ID: 801)
-
Kontakt:
- Jay Dwyer
- Telefonnummer: 415-502-5748
- E-mail: jay.dwyer@ucsf.edu
-
Torrance, California, Forenede Stater, 90502-2052
- Harbor University of California Los Angeles Center (Site ID: 603)
-
Kontakt:
- Mario Guerrero
- Telefonnummer: 323-457-1459
- E-mail: mguerrero@lundquist.org
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- University of Colorado Hospital (Site ID: 6101)
-
Kontakt:
- Nicola Haakonsen
- Telefonnummer: 303-724-5931
- E-mail: nicola.haakonsen@cuanschutz.edu
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20032
- Whitman-Walker Institute, Inc. (Site ID: 21791)
-
Kontakt:
- Avery Wimpelberg
- Telefonnummer: 202-797-3589
- E-mail: awimpelberg@whitman-walker.org
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Northwestern University (Site ID: 2701)
-
Kontakt:
- Sherryl L Wolfe
- Telefonnummer: 312-695-4997
- E-mail: s-wolfe@northwestern.edu
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Johns Hopkins University (Site ID: 201)
-
Kontakt:
- Rebecca L Becker
- Telefonnummer: 410-614-4036
- E-mail: rbecke22@jhmi.edu
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Massachusetts General Hospital (Site ID: 101)
-
Kontakt:
- Amy Sbrolla
- Telefonnummer: 617-726-5598
- E-mail: asbrolla@mgh.harvard.edu
-
Boston, Massachusetts, Forenede Stater, 02115
- Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107)
-
Kontakt:
- Hannah Jordan
- Telefonnummer: 617-732-4785
- E-mail: hcjordan@bwh.harvard.edu
-
-
New Jersey
-
Newark, New Jersey, Forenede Stater, 07103
- New Jersey Medical School Clinical Research Center (Site ID: 31786)
-
Kontakt:
- Christie Lyn Costanza
- Telefonnummer: 972-972-9069
- E-mail: costancl@njms.rutgers.edu
-
-
New York
-
New York, New York, Forenede Stater, 10010
- Weill Cornell Chelsea (Site ID: 7804)
-
Kontakt:
- Mauricio Vergara
- Telefonnummer: 212-746-7204
- E-mail: mav9177@med.cornell.edu
-
New York, New York, Forenede Stater, 10010
- Weill Cornell Uptown (Site ID: 7803)
-
Kontakt:
- Keisha Ballentine-Cargill
- Telefonnummer: 212-746-7804
- E-mail: keb4006@med.cornell.edu
-
New York, New York, Forenede Stater, 10032
- Columbia Physicians & Surgeons (P&S) (Site ID: 30329)
-
Kontakt:
- Brett T Gray
- Telefonnummer: 212-305-1570
- E-mail: bg2168@cumc.columbia.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27599-7215
- Chapel Hill (Site ID: 3201)
-
Kontakt:
- Erin Elizabeth Hoffman
- Telefonnummer: 919-843-0720
- E-mail: erin_hoffman@med.unc.edu
-
Greensboro, North Carolina, Forenede Stater, 27401-1020
- Greensboro (Site ID: 3203)
-
Kontakt:
- Kelly Phillips
- Telefonnummer: 336-832-7297
- E-mail: kelly.phillips@conehealth.com
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45267-0405
- Cincinnati Clinical Research Site (Site ID: 2401)
-
Kontakt:
- Michelle Saemann
- Telefonnummer: 513-584-2245
- E-mail: saemanmd@ucmail.uc.edu
-
Cleveland, Ohio, Forenede Stater, 44106
- Case Clinical Research Site (Site ID: 2501)
-
Kontakt:
- Julie Pasternak
- Telefonnummer: 216-844-2738
- E-mail: pasternak.julie@clevelandactu.org
-
Columbus, Ohio, Forenede Stater, 43210
- Ohio State University (Site ID: 2301)
-
Kontakt:
- Lindsay Summers
- Telefonnummer: 614-293-8529
- E-mail: lindsay.summers@osumc.edu
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15213
- University of Pittsburgh (Site ID: 1001)
-
Kontakt:
- Stacey Edick
- Telefonnummer: 412-383-1748
- E-mail: edicksm2@upmc.edu
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37204
- Vanderbilt Therapeutics (VT) (Site ID: 3652)
-
Kontakt:
- Beverly Woodward
- Telefonnummer: 615-936-8516
- E-mail: beverly.o.woodward@vumc.org
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Houston Advancing Research Team (Site ID: 31473)
-
Kontakt:
- Maria Laura Martinez
- Telefonnummer: 713-500-6718
- E-mail: maria.l.martinez@uth.tmc.edu
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98104
- University of Washington Positive Research (Site ID: 1401)
-
Kontakt:
- Allysson Angeldekao
- Telefonnummer: 503-715-7324
- E-mail: allysson@uw.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Documented HIV-1 infection
-
Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use
-
HIV-1 RNA >1000 copies/mL within 60 days prior to study entry
-
Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence
-
At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance
-
Adequate laboratory parameters within 60 days prior to study entry:
- Absolute neutrophil count >600/mm3
- Hemoglobin ≥7.0 g/dL
- Platelet count >50,000/μL
- AST and ALT ≤3 × upper limit of normal
- Estimated glomerular filtration rate >15 mL/min/1.73 m²
-
For participants of childbearing potential, negative pregnancy test at screening and within 24 hours prior to study entry
-
Ability and willingness to provide informed consent
-
Connected to a medical clinic with access to HIV care and antiretroviral therapy
Exclusion Criteria:
- Documented integrase strand transfer inhibitor (INSTI) resistance-associated mutations that may compromise cabotegravir activity
- Active hepatitis B infection, defined as positive hepatitis B surface antigen or detectable hepatitis B virus DNA
- Child-Pugh Class C cirrhosis
- No suitable injection site for cabotegravir administration due to implants, tattoos, or skin conditions interfering with injection site assessment
- Prior use of lenacapavir
- Receipt of HIV immunotherapeutic vaccines or HIV monoclonal antibodies within 6 months prior to study entry
- Serious medical or psychiatric condition
- Use of prohibited concomitant medications with lenacapavir or cabotegravir within 30 days prior to study entry
- Current pregnancy or breastfeeding
- Known allergy, hypersensitivity, or intolerance to cabotegravir, lenacapavir, or formulation components
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Long-Acting Lenacapavir Plus Long-Acting Cabotegravir
|
Long-acting subcutaneous lenacapavir administered every 24 weeks with oral loading doses at treatment initiation. Long-acting intramuscular cabotegravir administered every 8 weeks following initiation doses. Oral antiretroviral therapy provided as bridge therapy during interruptions or delays in long-acting treatment. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Proportion of participants achieving and maintaining viral suppression (no confirmed virologic failure) while receiving long-acting lenacapavir plus cabotegravir
Tidsramme: Baseline through Week 48
|
Baseline through Week 48
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tidsramme: Week 48
|
Week 48
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tidsramme: Week 48
|
Week 48
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tidsramme: Week 48
|
Week 48
|
|
|
Proportion of participants with Grade 3 or higher adverse events related to long-acting lenacapavir plus cabotegravir
Tidsramme: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir due to adverse events or intolerance
Tidsramme: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure on long-acting lenacapavir plus cabotegravir
Tidsramme: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tidsramme: Week 96
|
Week 96
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tidsramme: Week 96
|
Week 96
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tidsramme: Week 96
|
Week 96
|
|
|
Percentage of on-time long-acting injections
Tidsramme: Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir
Tidsramme: Baseline through Week 48 and through Week 96
|
Baseline through Week 48 and through Week 96
|
|
|
Plasma trough concentrations of lenacapavir and cabotegravir
Tidsramme: Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Change in CD4 cell count from baseline
Tidsramme: Week 48 and Week 96
|
Week 48 and Week 96
|
|
|
Participant-reported treatment satisfaction
Tidsramme: Week 48 and Week 96
|
HIV Treatment Satisfaction Questionnaire assesses participant satisfaction with the long-acting treatment. |
Week 48 and Week 96
|
|
Change in quality-of-life scores from baseline
Tidsramme: Week 48 and Week 96
|
Quality of life will be assessed using the Veterans Rand 12-item Health Survey (VR-12). Scores range from 0 to 100, with higher scores indicating better health-related quality of life. |
Week 48 and Week 96
|
|
Change in Patient Health Questionnaire-9 (PHQ-9) scores from baseline
Tidsramme: Week 48 and Week 96
|
Symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. |
Week 48 and Week 96
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure among participants not requiring oral bridge therapy
Tidsramme: Baseline through Week 48
|
Baseline through Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tidsramme: Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tidsramme: Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tidsramme: Week 48
|
Week 48
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- A5431
- 39159 (Anden identifikator: DAIDS-ES ID)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Individual participant data that underlie results in the publication after deidentification
IPD-delingstidsramme
Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH
IPD-delingsadgangskriterier
With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.
For what types of analyses? To achieve aims in the proposal approved by the ACTG.
By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .